25 Years of Consistent Dedication: With Customers as Our Top Priority, Committed to Enabling Innovation and Bringing Breakthrough Treatments to Patients Worldwide
Our Vision
Large Pharmas
Quality Speed
Every drug can be made, and every disease can be treated.Biotech Companies
Cost
3
3 Funding
Unique CRDMO (Contract Research, Development & Manufacturing Organization) Platform, Constantly Delivering Value to Customers Through Three Focused Core Business Segments
Research
Target to Hit Hit to Lead
Lead to PCC
Development
Preclinical Phase I Phase II Phase III
Manufacturing
Commercial Manufacturing
WuXi Biology
DEL/HTS, in vitro & in vivo Biology, Disease Models
WuXi Chemistry
CRDMO for Small Molecule and TIDES (Oligo & Peptide)
WuXi Testing
DMPK, Safety Assessment, Bioanalysis
4
Continued Strong Growth as A Leading Global CRDMO Company
~6,000
Active Customers across 30+
Countries over Past 12 Months
>4,000kL & >100kL
Total Reactor Volume of Small
Molecule & Peptide by End of 2025
>3,400
# of Molecules1in Small
Molecule CDMO Pipeline
RMB 45.5Bn
Total Revenue2in 2025, with Continuing Operations Growing 21.4% YoY
RMB 15.0Bn
Adjusted Non-IFRS Net Profit2in 2025, with 32.9% NPM (5.9pts YoY Increase)
RMB >55Bn
Strong Backlog1to Support
Sustainable Future Growth
5 Notes: 1. Data as of Q3 2025 for Continuing Operations (post divestiture of China-based clinical research services business).
2. Data per 2025 Positive Profit Alert (based on preliminary estimates); final results to be disclosed in the audited 2025 Annual Report (March 2026).
Continue to Invest in and Accelerate Enhancement of Global Capabilities & Capacities to Support Long-term Customer Demand and Future Growth
Boston New Jersey
Delaware
Munich Couvet
Changshu Wuxi
Tianjin Suzhou
Nantong
Changzhou
Taixing
San Diego
Chengdu Shanghai
Singapore
Jinshan
Nanjing
Wuhan
Reaching by end of 2025:
120,000m2 GLP lab facility
>4,000kL small molecule APIs capacity
>100,000L solid phase peptide synthesizer capacity
6 Note: including main R&D and manufacturing sites; sales offices not included.
Sites under expansion/construction
Existing sites
Integrated Research Platforms (WuXi Chemistry1, WuXi Biology & WuXi Testing) Collaborate to Build Early-Stage Capabilities and Funnel Opportunities to Enhance CRDMO Business Model
Generate Flow, Understand Trends, and Achieve Synergy Through Accelerated PCC2& IND2Delivery
>9k
Customers Supported (2011-2025)
Enable Innovation from Discovery1& Preclinical1
100%
Top20 Global Pharma Partnership (2011-2025)
Build Long-term Trust with Customers
~65%
New Customers Onboarded to the Company
Entry Point for CRDMO Platform
>430k
Compounds Delivered in Q4 2024 - Q3 2025
Generate Downstream Opportunities
~30%
Joint IND2 Projects Supported
Drive Accelerated Conversion and Delivery
7 Notes: 1. WuXi Chemistry - Drug Discovery, and WuXi Biology together represent the Discovery platform; WuXi Testing represents the Preclinical platform.
2. PCC, Preclinical Candidate; IND, Investigational New Drug.
WuXi Chemistry: "Follow the Molecule + Win the Molecule", Small Molecule CRDMO Pipeline
Efficiently Converts and Captures High-Quality Molecules, Delivering Sustained Growth
"R" 430,000+ Compounds
Q1-Q3 2025 Newly
Added Molecules to D&M Pipeline
Including 250 Molecules
in Total 621
Converted from R to D
2,889 Preclinical & Phase I 374 Phase II 87 Phase III16%
of Global Clinical Stage New Drugs (Q3 2025)
80
Commercial
8
Small Molecule D&M: Expansion of Phase III & Commercial Pipeline Continues to Drive Strong Growth
# of Small Molecule Phase III
& Commercial Drugs
Revenue of Small Molecule Phase III
& Commercial Drugs1
# of Molecules RMB billion
>150%
10.3
9.0
4.6
H1
5.4
107
87
127
167
152
+56%
80
72
61
50
57
66
80
2022 2023 2024 Q3 2025 2022 2023 2024 2025E
9 Note: 1. Excluding COVID-19 commercial project.
US FDA New Drug Approvals by Modality (2025)
1
3
4
30
17
Biologics
31%
Small Molecule 55%
CGT 7%
Oligo 5%
Peptide 2%
Supported 8 out of 30 Small Molecule Drugs Approved by US FDA in 2025, Timely Addressing Unmet Needs for Patients
Supported 27% of new drugs approved in 2025
10 Source: FDA (CDER & CBER); internal analysis. This analysis includes novel approvals and therapeutics only.
Securing Fast Growing Market for Glucagon-Like Peptide-1 Agonists (GLP-1)
Currently Supporting 24 GLP-1 Drugs
Clinical Stage Peptide Drugs
Clinical Stage Small Molecule Drugs
Marketed NCE
Drugs
out of 56
out of 36
1 out of 7
WuXi Chemistry is supporting 15 GLP-1 small molecule and peptide new drugs currently in Phase II and Phase III clinical trials, securing 25% of the market share
Estimated global sales of GLP-1 drugs in 2030 will reach $145B, 2.7x of the sales in 2024
11 Source: Evaluate Pharma, Mechanism of Action "Glucagon-like peptide 1 (GLP-1) receptor agonist", January 2026.
TIDES (Oligo & Peptide): Continued Rapid Business Growth Driven by Enhanced Capabilities and Fast Growing Capacities
TIDES Revenue Solid Phase Peptide Synthesizer
Total Reactor Volume
RMB billion Liter
>100,000
41,000
32,000
500
2,000
4,000
6,000
>90%
5.8
3.4
2.0
Q1-Q3
7.8
0.3
0.8
2020 2021 2022 2023 2024 2025E 2019 2020 2021 2022 2023 2024 2025
12
Navigating Through Cycles with Continued Growth in Revenue and Profitability
2025 Full-Year Again Beats Expectations: 21.4% YoY Growth in Continuing Operations Revenue, Total Revenue Reaching 45.5
Billion, and Adjusted Non-IFRS NPM% Further Improved to 32.9%
Revenue
Adjusted Non-IFRS Net Profit Attributable
to the Owners of the Company
RMB billion RMB billion
22.0%
22.4%
23.9%
26.9%
27.0%
32.9%
CAGR +22.4%
+15.8%
45.5
39.4
40.3
39.2
22.9
16.5
Adjusted Non-IFRS NPM%
CAGR +32.7%
+41.3%
15.0
9.4
10.9
10.6
3.6
5.1
2020 2021 2022 2023 2024 2025E12020 2021 2022 2023 2024 2025E1
13 Note: 1. Data per 2025 Positive Profit Alert (based on preliminary estimates); final results to be disclosed in the audited 2025 Annual Report (March 2026).
Sustained Positive Free Cash Flow Driven by Continued Business Growth, Efficient Operations and Constant Improvement of Financial Management Capabilities
Continue to Invest in Global Capabilities & Capacities, Talents, and Reward Shareholders
RMB billion
Operating Cash Flow
12.6
12.0
10.0
10.2
6.9
5.5
5.5-6.0
3.8
4.4
4.0
3.0
2020 2021 2022 2023 2024 2025E
14 Note: 1. Capex includes purchase of property, plant and equipment, other intangible assets and other long-term expenses.
Enabling Value Creation and Consistent Shareholder Returns
Basic Earnings per Share (EPS)1
Continue to Improve
Dividends & Share Buybacks
RMB20 Billion in Total Since IPO
RMB RMB billion
7.1
6.9
4.2
2.6
1.5
4.9
0.7
0.6
0.9
2.9
2019
2020
2021
2022
2023
2024
2025
2.0
~10x
6.7
3.0
3.3
3.3
1.8
0.7
1.1
2019 2020 2021 2022 2023 2024 2025E2
15 Notes: 1. Restate 2019 & 2020 EPS to reflect the changes in shares volume according to 2020 Profit Distribution Plan as per 2020 Annual Report.
2. Data per 2025 Positive Profit Alert (based on preliminary estimates); final results to be disclosed in the audited 2025 Annual Report (March 2026).
Advancing Sustainability, with Credibility Recognized by Global Authority Ratings & Initiatives
Achieved "AAA" from MSCI, "A" from CDP Climate Change & Water Security, and "Gold" from EcoVadis in 2025; Near-term
Achieved MSCI's highest "AAA"
rating for the first time in 2025; leadership ratings for 5 consecutive years
Improved to the highest
"A" rating in CDP Climate Change in 2025 for the first time
"A" rating in CDP Water
Security for 2 consecutive years in 2024-2025
"Gold" rating by EcoVadis
for 2 consecutive years in 2024-2025
Emissions Reduction Targets Validated by SBTi
Near-term emissions reduction targets validated by SBTi in 2025
16
Joined the United Nations Global Compact (UNGC) in 2024
Joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier partner in 2024
Named to S&P Global DJSI for 4 consecutive years
in 2021-2024
Unwavering Commitment to Guarding Customers' IP and Adhering to the Highest Standards
60
Information Security Audits by Global Customers in 2025, with 0 Critical Findings
of Quality & Compliance
741
Quality Audits & Inspections1 by Global Customers, Regulatory Authorities and Independent Third Parties in 2025
100%
Pass Rate with
0 Critical Findings
20
Main Operating Sites2are
ISO/IEC 27001 Certified
17 Notes: 1. Including 680 audits by customers, 56 inspections by regulatory authorities, and 5 audits by independent third parties.
2. Including all main operating sites in China for Continuing Operations (post divestiture of China-based clinical research services business).
Steering the Next 25 Years with Our Unique CRDMO Business Model and Operational Excellence, Positioning the Company to Continue Growth Through All Times
Continue to focus on our unique CRDMO core business, providing exceptional services to
01 customers and benefiting patients worldwide
02 Invest in and accelerate global enhancement of capabilities & capacities,
supporting long-term customer demand and innovation
03 Follow the science, and develop in-depth industry insights to secure new molecule opportunities, driving the next wave of accelerated growth
04 Maintain organizational agility and elevate operational excellence, continuing to deliver services with superior efficiency and quality
05 Sustain resilient profitability and operating cash flow, enabling value creation by consistent investment in business growth, talents and rewarding shareholders
18
19
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |